Hudson Bay Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-292,500
Closed -$37.4M – 1726
2026
Q1
$37.4M Buy
292,500
+92,500
+46% +$11.5M 0.13% 136
2025
Q4
$24.4M Buy
+200,000
New +$22.9M 0.08% 203
2025
Q2
– Sell
-575,000
Closed -$46.6M – 1680
2025
Q1
$46.6M Buy
575,000
+425,000
+283% +$38M 0.14% 139
2024
Q4
$13.5M Buy
+150,000
New +$14.5M 0.05% 307
2023
Q4
– Sell
-100,000
Closed -$7.3M – 912
2023
Q3
$7.3M Buy
+100,000
New +$7.99M 0.06% 213

Other funds holding XBI

Hudson Bay Capital Management's XBI Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 255 shares — an estimated $32.6K sold.

Hudson Bay Capital Management first reported a position in XBI in Q2 2020 and held it in 7 quarters. The position peaked at $11M in Q1 2025. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 255 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $32.6K.
  • Hudson Bay Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 7 quarters.
  • Hudson Bay Capital Management's State Street SPDR S&P Biotech ETF position peaked at $11M in Q1 2025.
  • 936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.